Dinesh Jothimani1, Mathew E Cramp2, Tim J S Cross3. 1. Institute of Liver Disease and Transplantation, Global Hospitals, Chennai, India. 2. The South West Liver Unit, Plymouth Hospitals, Derriford Road, Plymouth, Devon PL6 8DH, United Kingdom. 3. The Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, United Kingdom.
Abstract
BACKGROUND: Eighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH. METHOD: A retrospective observational study was carried out on all patients who received MMF for AIH. RESULTS: Twenty out of 117 patients with AIH received MMF due to AZA intolerance (18 patients) or refractory disease (2 patients). Median age of the study patients was 56 (18-79) years, Male, n = 3 (15%) and Female, n = 18 (85%). After a median follow-up period of 47 (5-83) months, 14 (73.6%) patients were still on MMF with biochemical remission, including 4 out of 5 patients with cirrhosis. One patient was lost to follow-up. Three patients were intolerant of MMF due to adverse events, and two had disease refractory to MMF. Both these patients with refractory disease to MMF were initially unresponsive to AZA therapy. CONCLUSION: MMF is a safe second line agent in patients with autoimmune hepatitis including those with cirrhosis.
BACKGROUND: Eighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH. METHOD: A retrospective observational study was carried out on all patients who received MMF for AIH. RESULTS: Twenty out of 117 patients with AIH received MMF due to AZA intolerance (18 patients) or refractory disease (2 patients). Median age of the study patients was 56 (18-79) years, Male, n = 3 (15%) and Female, n = 18 (85%). After a median follow-up period of 47 (5-83) months, 14 (73.6%) patients were still on MMF with biochemical remission, including 4 out of 5 patients with cirrhosis. One patient was lost to follow-up. Three patients were intolerant of MMF due to adverse events, and two had disease refractory to MMF. Both these patients with refractory disease to MMF were initially unresponsive to AZA therapy. CONCLUSION:MMF is a safe second line agent in patients with autoimmune hepatitis including those with cirrhosis.
Authors: Michael P Manns; Albert J Czaja; James D Gorham; Edward L Krawitt; Giorgina Mieli-Vergani; Diego Vergani; John M Vierling Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Maximilian Schmeding; Anja Kiessling; Ruth Neuhaus; Christoph Heidenhain; Marcus Bahra; Peter Neuhaus; Ulf P Neumann Journal: Transplantation Date: 2011-10-27 Impact factor: 4.939
Authors: Nazira Chatur; Alnoor Ramji; Vincent G Bain; Mang M Ma; Paul J Marotta; Cameron N Ghent; Leslie B Lilly; E Jenny Heathcote; Marc Deschenes; Samuel S Lee; Urs P Steinbrecher; Eric M Yoshida Journal: Liver Int Date: 2005-08 Impact factor: 5.828
Authors: T M Manzia; N De Liguori Carino; G Orlando; L Toti; L De Luca; D D'Andria; A Cardillo; A Anselmo; C U Casciani; G Tisone Journal: Transplant Proc Date: 2005 Jul-Aug Impact factor: 1.066
Authors: F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya Journal: J Hepatol Date: 1999-11 Impact factor: 25.083
Authors: Ira Inductivo-Yu; Atoya Adams; Robert G Gish; Adil Wakil; Natalie H Bzowej; R Todd Frederick; Maurizio Bonacini Journal: Clin Gastroenterol Hepatol Date: 2007-05-16 Impact factor: 11.382
Authors: Seung Woon Park; Soon Ho Um; Han Ah Lee; Sang Hyun Kim; Yura Sim; Sun Young Yim; Yeon Seok Seo; Ho Sang Ryu Journal: Clin Mol Hepatol Date: 2016-06-01